BCL-2 family antagonists for cancer therapy
Top Cited Papers
- 1 December 2008
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 7 (12) , 989-1000
- https://doi.org/10.1038/nrd2658
Abstract
Overexpression of members of the BCL-2 family of pro-survival proteins is commonly associated with unfavourable pathogenesis in cancer. The convergence of cytotoxic stress signals on the extended BCL-2 protein family provides the biological rationale for directly targeting this family to induce apoptotic cell death. Recently, several compounds have been described that inhibit the interaction between BCL- 2 family members and their natural ligand, a helical peptide sequence known as the BH3 domain. Here, we review preclinical and clinical data on these compounds, and recommend four criteria that define antagonists of the BCL-2 protein family.Keywords
This publication has 109 references indexed in Scilit:
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070Leukemia, 2007
- Structure-Based Design of Flavonoid Compounds As a New Class of Small-Molecule Inhibitors of the Anti-apoptotic Bcl-2 ProteinsJournal of Medicinal Chemistry, 2007
- Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1The EMBO Journal, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Development of a Potent Bcl-xLAntagonist Based on α-Helix MimicryJournal of the American Chemical Society, 2002
- The Hallmarks of CancerCell, 2000